(72) evaluated the clinical efficacy and immunomodulatory effects of the PARP inhibitor Olaparib in conjunction with the anti-PD-L1 antibody Durvalumab for managing recurrent ovarian cancer. The gene discussed is CD274; the disease is ovarian carcinoma.